Belgium's Galapagos signs $2 bln deal with US group Gilead
December 17, 2015 at 01:41 AM EST
BRUSSELS, Dec 17 (Reuters) - Belgian biotech company Galapagos has signed a development deal for drugs targeting inflammatory diseases potentially worth more than $2 billion with U.S. group Gilead.
